N-(3-bromophenyl)-3-cyclohexylpropanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-bromophenyl)-3-cyclohexylpropanamide
• 化学式: C₁₅H₂₀BrNO
• mdl: MFCD01834955
• 分子量: 310.23
• InChiKey: HIXKOBNZLQRVCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION
  申请人：ABIVAX

  公开号：EP3820850A1

  公开（公告）日：2021-05-19
• ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION
  申请人：ABIVAX

  公开号：US20210122732A1

  公开（公告）日：2021-04-29

  A compound of formula (Ie): wherein Y 1 represents an aryl group, X 2 represents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH 3 )NH— group, a —C(OH)(CH 2 OH)—, a group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO 2 — group, or a —SO 2 —NH— group, Y 2 represents a hydrogen atom, a hydroxyl group, a (C 1 -C 4 )alkoxy group, a —CHC(OH) 2 , a COOR f , wherein R f represents a hydrogen atom or a (C 1 -C 4 )alkyl group, a morpholinyl group, a dihydropyranyl group, a group, a group, a —PO(OR f )(OR′ f ) group, wherein R f and R′ f independently represents a hydrogen atom or a (C 1 -C 4 )alkyl group, an oxetanyl group, a —Si(CH 3 ) 3 group, a —NHCOO—(C 1 -C 4 )alkyl group, or a —CR 1 R 2 R 3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.
• [EN] PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION<br/>[FR] DÉRIVÉS DE PHÉNYLE/PYRIDYLE-N-PHÉNYLE/PYRIDYLE POUR LE TRAITEMENT D'UNE INFECTION PAR UN VIRUS À ARN
  申请人：ABIVAX

  公开号：WO2020011816A1

  公开（公告）日：2020-01-16

  The present invention relates to a compound of formula (Ie) wherein Y1 represents an aryl group, X2 represents a -O- group, a -NH- group, a -S- group, a-CO-NH- group, a -NH-CO-NH- group, a -NH-CO- group, a -CH(OH)- group, a -CH(COOH)NH- group, a -CH(COOCH3)NH- group, a -C(OH)(CH2OH)-, a (AA) group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a -SO2- group, or a -SO2-NH- group, Y2 represents a hydrogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a -CHC(OH)2, a COORf, wherein Rf represents a hydrogen atom or a (C1-C4)alkyl group, a morpholinyl group, a dihydropyranyl group, a (BB) group, a (CC) group, a -PO(ORf)(OR'f) group, wherein Rf and R'f independently represents a hydrogen atom or a (C1-C4)alkyl group, an oxetanyl group, a -Sί(CH3)3 group, a -NHCOO-(C1-C4)alkyl group, or a -CR1R2R3 group, or any of its pharmaceutically acceptable salt. The present invention further relates to pharmaceutical compositions containing them and to synthesis process for manufacturing them.